We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF’s multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and research institutions.
We are looking forward to Boehringer Ingelheim’s valuable contributions to the collaborative initiatives within the RDAF platform. Together, we remain steadfast in our mission to enhance access to diagnosis, treatment, and care for individuals afflicted with rare diseases in Switzerland.